Published on: November 2026
FINANCIAL PERFORMANCE AND OPERATING LEVERAGE IN SELECTED INDIAN PHARMACEUTICAL FIRMS
Adit Vijay Bhoite
Shirly Abraham
Article Status
Available Documents
Abstract
How to Cite this Paper
Bhoite, A. V. (2026). Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(11), 1-9. https://doi.org/10.55041/ijcope.v2i11.093
Bhoite, Adit. "Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms." International Journal of Creative and Open Research in Engineering and Management, vol. 02, no. 11, 2026, pp. 1-9. doi:https://doi.org/10.55041/ijcope.v2i11.093.
Bhoite, Adit. "Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms." International Journal of Creative and Open Research in Engineering and Management 02, no. 11 (2026): 1-9. https://doi.org/https://doi.org/10.55041/ijcope.v2i11.093.
References
Abrol, D. K., John, R., & Singh, N. (2026). The quality challenge for generic medicines in India: An industrial policy-sensitive perspective. Indian Journal of Medical Ethics, 11(2). https://doi.org/10.20529/IJME.2026.017Ajanta Pharma Limited. (2022, May 10). Statement of consolidated audited financial results for the quarter and year ended 31 March 2022 [Exchange filing, PDF pp. 4–5].
https://www.ajantapharma.com/assets/frontend/images/inv estors/files/quarterly_results/PressReleaseQ4%28Jan-Mar%292021-22.pdf
Ajanta Pharma Limited. (2024, May 2). Statement of consolidated audited financial results for the quarter and year ended 31 March 2024 [Exchange filing, PDF pp. 4–5].
https://www.ajantapharma.com/assets/frontend/images/inv estors/files/quarterly_results/PressRelease-Q4FY2024.pdf
Ajanta Pharma Limited. (2026, May 5). Statement of consolidated audited financial results for the quarter and year ended 31 March 2026 [Exchange filing, PDF pp. 4–5].
https://www.ajantapharma.com/assets/frontend/images/inv estors/files/quarterly_results/1777975848_PressRelease-Q4FY2026.pdf
Anderson, M. C., Banker, R. D., & Janakiraman, S. N. (2003). Are selling, general, and administrative costs “sticky”? Journal of Accounting Research, 41(1), 47–63. https://doi.org/10.1111/1475-679X.00095
Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of Management, 17(1), 99–120.
BSE Limited. (2024, July 2). Piramal Pharma Limited: Notice of 4th AGM and annual report 2023–24 [Exchange filing]. https://bseindia.com/xml-data/corpfiling/AttachHis/c09d72ec-f184-4eba-bcc8-93b26b846609.pdf
Business Standard. (2025, December 25). Just 1 in 4 MSME pharma units set for GMP transition as deadline nears. https://www.business-standard.com/industry/news/only-one-fourth-msme-drugmakers-comply-gmp-schedule-m-india-125122500521_1.html
Ethical Compliance & Review Process
- •All submissions are screened under plagiarism detection.
- •Review follows editorial policy.
- •Authors retain copyright.
- •Peer Review Type: Double-Blind Peer Review
- •Published on: Nov 17 2026
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. You are free to share and adapt this work for non-commercial purposes with proper attribution.

